Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.4.24.3 (
collagenase
)
18,340
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
We investigated how overexpression of human
TATA-box-binding protein
(
TBP
) affects the action of estrogen receptor (ER) and compared the response with that of other activators. When ER activates a simple promoter, consisting of a response element and either the
collagenase
or tk TATA box,
TBP
overexpression potentiates transcription.
TBP
potentiates only estrogen-induced and not basal transcription and does so independent of spacing between response element and TATA box.
TBP
overexpression also reduces autoinhibition by overexpressed ER, suggesting that one target of the autoinhibition may be
TBP
itself. Both AF-1 and AF-2 domains of ER are potentiated by
TBP
, and each domain binds
TBP
in vitro. Like ER, chimeric GAL4/VP16 and GAL4/Tat activators are also potentiated by
TBP
, as is the synergistic activation by ER and GAL4/VP16 on a complex promoter. Unlike ER, GAL4/Sp1 and GAL4/NF-I become less potent when
TBP
is overexpressed. Furthermore, synergy between ER and Sp1 or between ER and NF-I, whether these are supplied by transfected GAL4 fusions or by the endogenous genes, is inhibited by
TBP
overexpression. Thus, ER resembles VP16 in response to
TBP
overexpression and is different from Sp1 and NF-I, which predominate over ER in setting the response on complex promoters.
...
PMID:Transcriptional activators differ in their responses to overexpression of TATA-box-binding protein. 786 48